Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
The combination of high affinity IL-2 receptor agonists and immunosuppressants specifically expands antigen-specific regulatory T cells, addressing the limitations of conventional immunosuppressants by enhancing T-cell regulation and reducing autoimmune disease-related immune responses.
Patent Information
- Application Number
- PCT/US2024/027671
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-07
AI Technical Summary
Conventional immunosuppressants are broad-acting and often result in severe side effects, requiring lifelong therapy, while they fail to specifically target undesired immune responses associated with autoimmune diseases like diabetes, necessitating a more targeted approach to enhance regulatory T-cell production and durability.
Combining high affinity IL-2 receptor agonists with immunosuppressants, such as rapamycin, to synergistically induce and expand antigen-specific regulatory T cells, reducing CD8+ T cells and increasing double-negative T cells, thereby promoting tolerogenic immune responses.
This combination therapy effectively enhances the production and durability of antigen-specific regulatory T cells, reducing undesired immune responses and potentially treating or preventing autoimmune diseases like Type 1 diabetes with fewer side effects.
Smart Images

Figure US2024027671_07112024_PF_FP_ABST
Abstract
Citation Information
Patent Citations
Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20020086049A1
Targeted and high density drug loaded polymeric materials
US20060002852A1
Molecular antigen array
US20060222652A1
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US20060251677A1
nanoparticles
US20080145441A1
